InspireMD, Inc. (NSPR)
NASDAQ: NSPR · IEX Real-Time Price · USD
2.360
-0.030 (-1.26%)
At close: Jul 19, 2024, 4:00 PM
2.385
+0.025 (1.06%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
InspireMD Revenue
InspireMD had revenue of $6.48M in the twelve months ending March 31, 2024, with 23.91% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $1.51M with 21.95% year-over-year growth. In the year 2023, InspireMD had annual revenue of $6.21M with 20.00% growth.
Revenue (ttm)
$6.48M
Revenue Growth
+23.91%
P/S Ratio
9.09
Revenue / Employee
$98,136
Employees
66
Market Cap
58.91M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6.21M | 1.03M | 20.00% |
Dec 31, 2022 | 5.17M | 676.00K | 15.04% |
Dec 31, 2021 | 4.50M | 2.01M | 80.89% |
Dec 31, 2020 | 2.49M | -1.24M | -33.22% |
Dec 31, 2019 | 3.72M | 120.00K | 3.33% |
Dec 31, 2018 | 3.60M | 840.00K | 30.42% |
Dec 31, 2017 | 2.76M | 867.00K | 45.78% |
Dec 31, 2016 | 1.89M | -416.00K | -18.01% |
Dec 31, 2015 | 2.31M | -508.00K | -18.03% |
Dec 31, 2014 | 2.82M | -2.06M | -42.17% |
Jun 30, 2013 | 4.87M | -476.00K | -8.90% |
Jun 30, 2012 | 5.35M | -655.00K | -10.91% |
Dec 31, 2011 | 6.00M | 1.06M | 21.32% |
Dec 31, 2010 | 4.95M | 1.54M | 45.09% |
Dec 31, 2009 | 3.41M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Rockwell Medical | 86.62M |
HOOKIPA Pharma | 53.55M |
Cryo-Cell International | 31.64M |
ProPhase Labs | 28.72M |
Enzo Biochem | 4.72M |
VolitionRx | 797.03K |
NSPR News
- 7 weeks ago - InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024 - GlobeNewsWire
- 2 months ago - InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th - GlobeNewsWire
- 3 months ago - InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 4 months ago - InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024 - GlobeNewsWire
- 4 months ago - InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th - GlobeNewsWire
- 5 months ago - InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System - GlobeNewsWire